CVS Health Corp. is moving to promote the use of biosimilar and follow-on competition to Amgen Inc’s. granulocyte-colony stimulating factor drug Neupogen (filgrastim) and Sanofi’s glargine insulin Lantus by excluding those drugs from coverage in its standard national formulary in 2017.
The standard formula covers approximately 25 million individuals and is among the formulary options CVS offers to its payer clients
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?